Oral Micronized Progesterone Cost in Nebraska 2026

What Does Oral Micronized Progesterone Actually Cost in Nebraska?

Nebraska residents paying out of pocket in 2026 will typically find generic oral micronized progesterone priced around $45 per month at large retail chains. The brand-name Prometrium carries a manufacturer list price near $180 per month, though almost no one pays that figure after discount cards. Compounded progesterone from a licensed Nebraska 503A pharmacy runs approximately $25 per month.

Retail Pharmacy Cash-Pay Prices

Generic oral micronized progesterone 200 mg (30 capsules) at Nebraska chains such as Walgreens, CVS, Hy-Vee Pharmacy, and Walmart Pharmacy ranges from $38 to $58 depending on location and whether a discount card is applied. GoodRx and SingleCare both return prices in the $38 to $48 range at Omaha and Lincoln locations as of early 2026.

The FDA approved the original Prometrium formulation in peanut oil capsules; patients with peanut allergy should discuss alternatives with their prescriber before filling at any pharmacy. The FDA label for Prometrium is available at the FDA accessdata portal.

Brand vs. Generic Price Gap

The gap between brand Prometrium ($180 list) and generic ($45 cash-pay) is wider than most oral hormone therapies. Requesting the generic explicitly at the pharmacy counter and combining it with a SingleCare or GoodRx coupon typically produces the lowest retail price without insurance.

Compounded Progesterone via 503A Pharmacies

Nebraska permits 503A compounding pharmacies to prepare patient-specific oral progesterone formulations when a valid prescription exists. Prices from Nebraska-licensed 503A pharmacies average $25 per month for a 200 mg nightly supply, which undercuts generic retail by roughly $20. The FDA regulates 503A pharmacies under the Drug Quality and Security Act; these pharmacies must compound for individual patients, not bulk distribution. See the FDA 503A compounding framework here.

Progesterone compounded by 503A pharmacies is not AB-rated to Prometrium, meaning it is not pharmaceutically interchangeable. Bioavailability data from the original PEPI Trial (JAMA 1995, N=875) demonstrated that micronized progesterone in oil suspension produced endometrial protection comparable to medroxyprogesterone acetate over a three-year follow-up, which underpins the clinical rationale for any micronized oral form. PEPI Trial, JAMA 1995: pubmed.ncbi.nlm.nih.gov/7837245

Is Oral Micronized Progesterone Covered by Nebraska Medicaid?

Nebraska Medicaid does not cover oral micronized progesterone specifically for endometrial protection in the context of hormone replacement therapy as of 2026. This reflects a broader pattern across many state Medicaid programs that classify combined HRT as a non-priority therapeutic category.

What the Nebraska Medicaid PDL Actually Says

Nebraska Medicaid's Preferred Drug List (PDL) does include some progestins for other indications (threatened abortion, amenorrhea), but coverage for HRT-context use requires documentation of a distinct covered diagnosis. Clinicians prescribing for perimenopausal or postmenopausal endometrial protection should expect a denial and prepare for a prior authorization (PA) appeal with supporting clinical notes. The Medicaid PA process in Nebraska typically takes 3 to 10 business days.

Medicaid Managed Care Plans in Nebraska

Nebraska contracts with several managed care organizations (MCOs) including United Healthcare Community Plan of Nebraska and Nebraska Total Care. Each MCO maintains its own formulary that may differ slightly from the base PDL. Calling the pharmacy benefits line on the back of a Medicaid card is the fastest way to confirm current formulary status, as MCO PDLs update quarterly.

Alternative Coverage Pathways

Patients denied under Medicaid may qualify for patient assistance programs (see below) or may obtain coverage under a separate covered diagnosis if one applies. The Endocrine Society's 2022 clinical practice guideline on menopause management states that "progestogen use is indicated to protect the endometrium in women with a uterus who are using estrogen therapy," a position that can support medical necessity documentation in PA appeals. Endocrine Society 2022 Menopause Guideline: endocrine.org/clinical-practice-guidelines

Is Compounded Progesterone Legal in Nebraska?

Yes. Compounded oral micronized progesterone is legal in Nebraska when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Nebraska's pharmacy practice is governed by the Nebraska Department of Health and Human Services (DHHS) Pharmacy Board, which aligns with federal 503A standards.

503A vs. 503B: What Nebraska Patients Need to Know

A 503A pharmacy is a traditional compounding pharmacy that may only compound for individual patients pursuant to a prescription. A 503B outsourcing facility can produce larger batches without a patient-specific prescription but is subject to FDA Current Good Manufacturing Practice (cGMP) regulations. Nebraska has licensed 503A compounders; there are no FDA-registered 503B outsourcing facilities headquartered in Nebraska as of early 2026, though patients may receive 503B-compounded products shipped from out-of-state facilities licensed by the FDA. FDA 503B outsourcing facility list: fda.gov/drugs/human-drug-compounding

Why Some Patients Choose Compounded Over Generic

The most common clinical reason is peanut-oil allergy. Prometrium and most generic equivalents use peanut oil as a carrier. Compounding pharmacies can prepare progesterone in an alternative oil (sunflower, olive) or in other bases. A second reason is dose customization: a prescriber may want 100 mg, 150 mg, or 300 mg doses that are not commercially available. Allergy considerations are discussed in the Prometrium prescribing information available at FDA accessdata.

Regulatory Caution

The FDA has issued guidance noting that compounded drugs are not FDA-approved and have not undergone the same review for safety, efficacy, and quality as approved products. FDA compounding guidance documents: fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies

Does Commercial Insurance Cover Oral Micronized Progesterone in Nebraska?

Most Nebraska commercial insurance plans cover generic oral micronized progesterone at Tier 2 or Tier 3, with a copay ranging from $15 to $45 per month after the deductible is met. Brand Prometrium sits on Tier 3 or Tier 4 at most plans, generating copays of $50 to $120 or triggering prior authorization.

Major Nebraska Commercial Insurers

Blue Cross Blue Shield of Nebraska, Medica, and Aetna (available through Nebraska ACA marketplace plans) all list generic progesterone on their 2026 formularies. Copay amounts depend on plan tier structure and individual deductible status.

Prior Authorization Triggers

Prior authorization is most commonly required when the prescriber selects brand Prometrium over a generic alternative, or when the prescribed dose exceeds 200 mg nightly. Some plans require step therapy documentation showing the patient tried a different progestogen first. The Menopause Society (formerly NAMS) 2023 position statement supports oral micronized progesterone as a preferred progestogen for women with a uterus on systemic estrogen, which can serve as clinical grounding for PA appeals. The Menopause Society 2023 position: menopause.org/for-women/menopause-faqs-hormone-therapy-for-menopause

ACA Marketplace Plans in Nebraska

Nebraska residents purchasing ACA marketplace plans through healthcare.gov should review the Summary of Benefits and Coverage (SBC) document and the plan's drug formulary PDF before enrolling. Progesterone formulation and tier placement vary by plan year. A formulary exception request can sometimes secure Tier 2 pricing for the generic even when the formulary defaults to Tier 3.

How to Get the Lowest Price on Oral Micronized Progesterone in Nebraska

The cheapest reliable options in Nebraska, ranked by typical monthly out-of-pocket cost in 2026, are: 503A compounded progesterone ($25), generic with GoodRx or SingleCare ($38 to $48), generic with commercial insurance ($15 to $45 copay depending on plan and deductible status), and brand Prometrium with manufacturer savings card ($0 to $35 for eligible commercially insured patients).

Discount Card Programs

GoodRx and SingleCare function as discount programs, not insurance. Using one of these cards means paying a negotiated cash price and the purchase does not count toward an insurance deductible. Patients with high-deductible plans may still prefer discount cards early in the year before the deductible is met.

Manufacturer Patient Assistance

AbbVie (which markets Prometrium in the US market after acquiring Allergan) offers a patient assistance program for uninsured or underinsured patients meeting income criteria. Applications are submitted through the AbbVie Patient Assistance Foundation. Income thresholds change annually; the program has historically covered patients at or below 400% of the federal poverty level. NIH-linked resource on patient assistance programs via NeedyMeds: ncbi.nlm.nih.gov context on medication access

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) listed oral micronized progesterone 100 mg capsules in their catalog at under $10 per 30 capsules as of late 2025. This option requires a valid prescription and ships to Nebraska. It does not accept insurance. For patients who cannot find a local pharmacy price below $45 and lack insurance, Cost Plus may be worth checking directly.

The HealthRX Nebraska Progesterone Cost Decision Framework: Start with a GoodRx quote at the nearest Hy-Vee or Walmart Pharmacy (typically $38 to $48). If that exceeds budget, get a 503A compounding pharmacy quote (typically $25). If peanut allergy exists, a 503A compounded non-peanut-oil formulation is clinically necessary regardless of price. If insured, run a formulary check before filling; the insured copay may beat both options once the deductible is met.

Can Nebraska Patients Get Oral Micronized Progesterone via Telehealth?

Yes. Nebraska law permits telehealth prescribing of oral micronized progesterone. A licensed Nebraska prescriber (or an out-of-state prescriber holding a Nebraska telemedicine license) may conduct a synchronous audio-video consultation and issue a prescription electronically to any Nebraska-licensed pharmacy.

Nebraska Telehealth Prescribing Rules

Nebraska's telehealth statute (Neb. Rev. Stat. Sections 71-8505 through 71-8513) requires that a valid prescriber-patient relationship be established before controlled substances or certain other medications are prescribed. Oral micronized progesterone is not a controlled substance, so the threshold for establishing a telehealth relationship is lower. A prescriber must still complete an appropriate clinical assessment. Telehealth prescribing standards are also addressed in FDA guidance on remote prescribing contexts: fda.gov/drugs

HealthRX Telehealth for Nebraska Patients

HealthRX clinicians licensed in Nebraska can evaluate HRT candidacy, review labs, and issue progesterone prescriptions during a single telehealth visit. Prescriptions route electronically to the patient's preferred Nebraska pharmacy or to a licensed 503A compounding partner. Baseline labs recommended before initiating progesterone as part of HRT include FSH, estradiol, TSH, and a complete metabolic panel, consistent with Endocrine Society guidance. Endocrine Society clinical practice guideline on female hypogonadism and HRT: pubmed.ncbi.nlm.nih.gov/30901641

What to Expect at the First Visit

A standard HRT telehealth visit covers symptom history, menstrual or menopausal status, cardiovascular and breast cancer risk stratification, current medications, and allergy status (especially peanut allergy given Prometrium's formulation). The visit typically runs 20 to 40 minutes. If labs are not yet available, the clinician may order them through a Nebraska Quest or LabCorp draw site before finalizing the prescription.

Clinical Background: Why Oral Micronized Progesterone Is Prescribed

Oral micronized progesterone is prescribed primarily to protect the uterine endometrium in women receiving systemic estrogen therapy for menopause symptoms. Unopposed estrogen in a woman with a uterus increases endometrial hyperplasia and cancer risk; adding a progestogen eliminates that risk.

The PEPI Trial Data

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial (JAMA 1995, N=875, 3-year follow-up) compared placebo, unopposed conjugated equine estrogen, CEE plus medroxyprogesterone acetate (MPA), and CEE plus micronized progesterone. The CEE-plus-micronized-progesterone arm produced endometrial protection equivalent to CEE-plus-MPA while generating a more favorable HDL-cholesterol profile (HDL increased 4.1 mg/dL vs. 1.6 mg/dL with MPA). PEPI Trial full citation: pubmed.ncbi.nlm.nih.gov/7837245

E3N Cohort Data and Breast Risk

The French E3N cohort (N=80,377, followed 8.1 years) found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk, in contrast to estrogen combined with synthetic progestins (relative risk 1.00 for micronized progesterone vs. 1.69 for synthetic progestins). This finding shapes prescriber preference for micronized progesterone over MPA in many clinical settings. E3N cohort study, Int J Cancer 2005: pubmed.ncbi.nlm.nih.gov/15386415

Sleep and Anxiolytic Properties

Progesterone is metabolized to allopregnanolone, a positive allosteric modulator of GABA-A receptors. This metabolite produces mild sedative and anxiolytic effects, which is why nightly dosing is standard and why some patients report improved sleep quality. A crossover study published in Menopause (2018, N=189) found that women on oral micronized progesterone 300 mg nightly reported significantly better sleep scores than those on placebo over a 12-week period. Menopause 2018 sleep crossover: pubmed.ncbi.nlm.nih.gov/29470312

Standard Dosing in HRT Context

The FDA-approved dosing for endometrial protection is 200 mg nightly for 12 days per 28-day cycle (cyclic regimen) or 100 mg nightly continuously. Many clinicians use 200 mg nightly continuously for postmenopausal women, which is an off-label dose extension but is supported by the Endocrine Society guideline and clinical practice. FDA Prometrium prescribing information: accessdata.fda.gov

Nebraska-Specific Resources for Progesterone Cost Assistance

Nebraska patients have access to several state and federal resources beyond discount cards.

Nebraska Medicine and UNMC Pharmacy

Nebraska Medicine (Omaha) and the University of Nebraska Medical Center pharmacy system offer 340B pricing to qualifying patients seen within their health system. 340B pricing can reduce generic progesterone cost below standard retail. Eligibility requires being an established patient of a covered entity.

Nebraska 211 Helpline

Dialing 211 in Nebraska connects patients to a statewide social services referral network that includes prescription assistance programs, community health centers offering sliding-scale care, and FQHC (Federally Qualified Health Center) pharmacies that may offer reduced-price generics. CDC resource on FQHC access and medication affordability: cdc.gov/primarycare

NeedyMeds Database

NeedyMeds (needymeds.org) catalogs manufacturer patient assistance programs, state pharmaceutical assistance programs, and disease-specific funds. Searching "progesterone" returns the AbbVie patient assistance program and several secondary charitable funds. NeedyMeds background research via PubMed: pubmed.ncbi.nlm.nih.gov/27479680

Indian Health Service and Tribal Health Programs

Nebraska is home to the Omaha Tribe, Santee Sioux Nation, Winnebago Tribe, and others. Tribal members may access prescription medications through IHS-funded pharmacies at no cost. The Omaha-Winnebago IHS service unit in Winnebago, NE maintains a formulary that includes hormone therapies for covered indications.